DK3079744T3 - Tørpulverinhalator - Google Patents
Tørpulverinhalator Download PDFInfo
- Publication number
- DK3079744T3 DK3079744T3 DK14799494.1T DK14799494T DK3079744T3 DK 3079744 T3 DK3079744 T3 DK 3079744T3 DK 14799494 T DK14799494 T DK 14799494T DK 3079744 T3 DK3079744 T3 DK 3079744T3
- Authority
- DK
- Denmark
- Prior art keywords
- inhaler
- dose
- dry powder
- budesonide
- opening
- Prior art date
Links
- 229940112141 dry powder inhaler Drugs 0.000 title claims abstract description 12
- 239000003814 drug Substances 0.000 claims abstract description 67
- PJFHZKIDENOSJB-UHFFFAOYSA-N Budesonide/formoterol Chemical compound C1=CC(OC)=CC=C1CC(C)NCC(O)C1=CC=C(O)C(NC=O)=C1.C1CC2=CC(=O)C=CC2(C)C2C1C1CC3OC(CCC)OC3(C(=O)CO)C1(C)CC2O PJFHZKIDENOSJB-UHFFFAOYSA-N 0.000 claims abstract description 54
- 239000000843 powder Substances 0.000 claims abstract description 42
- 229940080593 budesonide / formoterol Drugs 0.000 claims abstract description 31
- 239000002245 particle Substances 0.000 claims abstract description 31
- VOVIALXJUBGFJZ-KWVAZRHASA-N Budesonide Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@@H]2[C@@H]1[C@@H]1C[C@H]3OC(CCC)O[C@@]3(C(=O)CO)[C@@]1(C)C[C@@H]2O VOVIALXJUBGFJZ-KWVAZRHASA-N 0.000 claims abstract description 29
- 229960004436 budesonide Drugs 0.000 claims abstract description 29
- 238000009826 distribution Methods 0.000 claims abstract description 19
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 claims abstract description 18
- 239000008101 lactose Substances 0.000 claims abstract description 18
- OBRNDARFFFHCGE-PERKLWIXSA-N (S,S)-formoterol fumarate Chemical compound OC(=O)\C=C\C(O)=O.C1=CC(OC)=CC=C1C[C@H](C)NC[C@@H](O)C1=CC=C(O)C(NC=O)=C1.C1=CC(OC)=CC=C1C[C@H](C)NC[C@@H](O)C1=CC=C(O)C(NC=O)=C1 OBRNDARFFFHCGE-PERKLWIXSA-N 0.000 claims abstract description 16
- 229960000193 formoterol fumarate Drugs 0.000 claims abstract description 16
- 238000004891 communication Methods 0.000 claims description 17
- 239000012530 fluid Substances 0.000 claims description 17
- 208000006673 asthma Diseases 0.000 claims description 15
- BPZSYCZIITTYBL-UHFFFAOYSA-N formoterol Chemical compound C1=CC(OC)=CC=C1CC(C)NCC(O)C1=CC=C(O)C(NC=O)=C1 BPZSYCZIITTYBL-UHFFFAOYSA-N 0.000 claims description 15
- 229960002848 formoterol Drugs 0.000 claims description 15
- 239000000203 mixture Substances 0.000 claims description 14
- 238000007789 sealing Methods 0.000 claims description 14
- 239000004480 active ingredient Substances 0.000 claims description 9
- 208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 claims description 8
- 208000023504 respiratory system disease Diseases 0.000 claims description 7
- 239000008194 pharmaceutical composition Substances 0.000 claims description 4
- 238000011282 treatment Methods 0.000 claims description 4
- 229940079593 drug Drugs 0.000 claims 6
- 230000004913 activation Effects 0.000 claims 3
- 229960001375 lactose Drugs 0.000 description 13
- 125000006850 spacer group Chemical group 0.000 description 9
- 238000004088 simulation Methods 0.000 description 8
- 238000009472 formulation Methods 0.000 description 7
- 238000012360 testing method Methods 0.000 description 7
- 238000000034 method Methods 0.000 description 6
- 239000010419 fine particle Substances 0.000 description 5
- 210000004072 lung Anatomy 0.000 description 4
- 239000000523 sample Substances 0.000 description 4
- 238000005070 sampling Methods 0.000 description 4
- 238000003466 welding Methods 0.000 description 4
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 3
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- 239000004743 Polypropylene Substances 0.000 description 3
- 239000004793 Polystyrene Substances 0.000 description 3
- DHKHKXVYLBGOIT-UHFFFAOYSA-N acetaldehyde Diethyl Acetal Natural products CCOC(C)OCC DHKHKXVYLBGOIT-UHFFFAOYSA-N 0.000 description 3
- 150000001241 acetals Chemical class 0.000 description 3
- 239000000463 material Substances 0.000 description 3
- 239000002184 metal Substances 0.000 description 3
- 239000004033 plastic Substances 0.000 description 3
- -1 polypropylene Polymers 0.000 description 3
- 229920001155 polypropylene Polymers 0.000 description 3
- 229920002223 polystyrene Polymers 0.000 description 3
- WSVLPVUVIUVCRA-KPKNDVKVSA-N Alpha-lactose monohydrate Chemical compound O.O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O WSVLPVUVIUVCRA-KPKNDVKVSA-N 0.000 description 2
- 239000013543 active substance Substances 0.000 description 2
- 238000004128 high performance liquid chromatography Methods 0.000 description 2
- 238000007373 indentation Methods 0.000 description 2
- 238000009666 routine test Methods 0.000 description 2
- 238000004704 ultra performance liquid chromatography Methods 0.000 description 2
- HTTDNJMHFSPRCL-LWOQYNTDSA-N C[IH][C@H](C1)C1N1CC1 Chemical compound C[IH][C@H](C1)C1N1CC1 HTTDNJMHFSPRCL-LWOQYNTDSA-N 0.000 description 1
- LERNTVKEWCAPOY-VOGVJGKGSA-N C[N+]1(C)[C@H]2C[C@H](C[C@@H]1[C@H]1O[C@@H]21)OC(=O)C(O)(c1cccs1)c1cccs1 Chemical compound C[N+]1(C)[C@H]2C[C@H](C[C@@H]1[C@H]1O[C@@H]21)OC(=O)C(O)(c1cccs1)c1cccs1 LERNTVKEWCAPOY-VOGVJGKGSA-N 0.000 description 1
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical class OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 1
- 206010039085 Rhinitis allergic Diseases 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 230000000996 additive effect Effects 0.000 description 1
- 239000000048 adrenergic agonist Substances 0.000 description 1
- 229940126157 adrenergic receptor agonist Drugs 0.000 description 1
- 201000010105 allergic rhinitis Diseases 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 208000016709 aortopulmonary window Diseases 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 238000004140 cleaning Methods 0.000 description 1
- 229940000425 combination drug Drugs 0.000 description 1
- 238000002648 combination therapy Methods 0.000 description 1
- 239000003246 corticosteroid Substances 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 239000006185 dispersion Substances 0.000 description 1
- 229940088679 drug related substance Drugs 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 239000004744 fabric Substances 0.000 description 1
- 238000000227 grinding Methods 0.000 description 1
- 230000003434 inspiratory effect Effects 0.000 description 1
- 238000010902 jet-milling Methods 0.000 description 1
- 229960001021 lactose monohydrate Drugs 0.000 description 1
- 229940071648 metered dose inhaler Drugs 0.000 description 1
- 230000035515 penetration Effects 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 238000011321 prophylaxis Methods 0.000 description 1
- 230000000717 retained effect Effects 0.000 description 1
- 239000012488 sample solution Substances 0.000 description 1
- 238000007873 sieving Methods 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 238000010561 standard procedure Methods 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 238000002636 symptomatic treatment Methods 0.000 description 1
- 229960000257 tiotropium bromide Drugs 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- 230000000007 visual effect Effects 0.000 description 1
- 239000002699 waste material Substances 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
- 230000003442 weekly effect Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
- A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/007—Pulmonary tract; Aromatherapy
- A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
- A61K9/0075—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a dry powder inhaler [DPI], e.g. comprising micronized drug mixed with lactose carrier particles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M15/00—Inhalators
- A61M15/0001—Details of inhalators; Constructional features thereof
- A61M15/0005—Details of inhalators; Constructional features thereof with means for agitating the medicament
- A61M15/0006—Details of inhalators; Constructional features thereof with means for agitating the medicament using rotating means
- A61M15/0008—Details of inhalators; Constructional features thereof with means for agitating the medicament using rotating means rotating by airflow
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M15/00—Inhalators
- A61M15/0001—Details of inhalators; Constructional features thereof
- A61M15/0021—Mouthpieces therefor
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M15/00—Inhalators
- A61M15/0065—Inhalators with dosage or measuring devices
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M15/00—Inhalators
- A61M15/0086—Inhalation chambers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M2202/00—Special media to be introduced, removed or treated
- A61M2202/06—Solids
- A61M2202/064—Powder
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M2206/00—Characteristics of a physical parameter; associated device therefor
- A61M2206/10—Flow characteristics
- A61M2206/16—Rotating swirling helical flow, e.g. by tangential inflows
Landscapes
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pulmonology (AREA)
- Anesthesiology (AREA)
- Biomedical Technology (AREA)
- Hematology (AREA)
- Heart & Thoracic Surgery (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Epidemiology (AREA)
- Biophysics (AREA)
- Otolaryngology (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pain & Pain Management (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Claims (15)
1. Budesonid/formoteroltørpulverinhalator (10), der omfatter: en beholder (14), der indeholder et tørpul verlægemiddel, og et arrangement til indgivelse af en afmålt dosis af lægemidlet fra beholderen (14); en cyklondeagglomerator (10’) til opbrydning af agglomerater af tørpul verlægemidlet; og en indgivelsespassage (34) til dirigering af en inhalationsinduceret luftstrøm gennem et mundstykke (24), idet indgivelsespassagen (34) strækker sig til den afmålte lægemiddeldosis, kendetegnet ved, at lægemidlet består af aktiv bestanddel og bærer, hvor den aktive bestanddel omfatter mikroniseret formoterolfumarat og mikroniseret budesonid, og hvor bæreren består af lactose med en partikelstørrelsesfordeling på dlO = 20-65 pm, d50 = 80-120 pm, d90 = 130-180 pm og <10 pm = <10 %.
2. Inhalator (10) ifølge krav 1, hvor deagglomeratoren (10’) omfatter: en indvendig væg (12’), der definerer et hvirvelkammer (14’), der strækker sig langs en akse (A’) fra en første ende (18’) til en anden ende (20’); en tørpulvertilførselsåbning (22') i den første ende (18’) af hvirvelkammeret (14’) til tilvejebringelse af fluidforbindelse mellem inhalatorens indgivelsespassage (34) og den første ende (18’) af hvirvelkammeret (14’); mindst én indgangsåbning (24', 25') i den indvendige væg (12’) af hvirvelkammeret (14’) stødende op til den første ende (18’) af hvirvelkammeret (14’), der tilvejebringer fluidforbindelse mellem et område uden for deagglomeratoren (10’) og den første ende (18’) af hvirvelkammeret (14’); en udgangsåbning (32'), der tilvejebringer fluidforbindelse mellem den anden ende (20’) af hvirvelkammeret (14’) og et område uden for deagglomeratoren (10’); og blade (26') ved den første ende (18’) af hvirvelkammeret (14’), der strækker sig mindst delvist radialt udefter fra aksen (A’) af kammeret (14’), hvor hvert af bladene (26’) har en skrå overflade, der vender mindst delvist i en retning på tværs af aksen (A’); hvorved et åndedrætsinduceret lavt tryk ved udgangsåbningen (32’) bevirker, at luft strømmer ind i hvirvelkammeret (14’) gennem tørpulvertilførselsåbningen (22’) og indgangsåbningen (24', 25').
3. Inhalator (10) ifølge krav 1 eller 2, hvor beholderen (14) er en forseglet beholder (14), der indbefatter en afgivelsesåbning (44), og inhalatoren (10) endvidere omfatter en kanal, der står i forbindelse med afgivelsesåbningen og indbefatter en trykudligningsåbning (116); en kanal (114), der tilvejebringer fluidforbindelse mellem et indre af den forseglede beholder (14) og kanalens trykudligningsåbning (116); og en bægerenhed, der er aftageligt (96) modtaget i kanalen og indbefatter en indskæring (102) tilpasset til at modtage lægemiddel, når den flugter med afgivelsesåbningen (44), en første forseglingsoverflade (118) tilpasset til at forsegle afgivelsesåbningen (44), når indskæringen (102) ikke flugter med afgivelsesåbningen (44), og en anden forseglingsoverflade (124) tilpasset til at forsegle trykudligning s åbningen (44), når indskæringen (102) flugter med afgivelsesåbningen (44) og til at fjerne forseglingen fra trykudligningsåbningen (116), når indskæringen (102) ikke flugter med afgivelsesåbningen (44).
4. Inhalator (10) ifølge et hvilket som helst foregående krav, hvor partikelstørrelsesfordelingen af lactosen er dlO = 20-65 pm, d50 = 80-120 pm, d90 = 130-180 pm og <10 pm = <6%.
5. Inhalator (10) ifølge et hvilket som helst foregående krav, hvor partikelstørrelsesfordelingen af budesonidet er dlO <1 pm, d50 = <5 pm, d90 = <10 pm og NLT 99 % < 10 pm.
6. Inhalator (10) ifølge krav 5, hvor partikelstørrelsesfordelingen budesonidet er dlO < 1 pm, d50 = 1-3 pm, d90 = 3-6 pm og NLT 99 % < 10 pm.
7. Inhalator (10) ifølge et hvilket som helst foregående krav, hvor partikelstørrelsesfordelingen af formoterolfumaratet er dlO <1 pm, d50 = <5 pm, d90 = <10 pm og NLT 99 % <10 pm.
8. Inhalator (10) ifølge krav 7, hvor partikelstørrelsesfordelingen af formoterolfumaratet er dlO <1 pm, d50 = 1-3 pm, d90 = 3.5-6 pm og NLT 99 % <10 pm.
9. Inhalator (10) ifølge et hvilket som helst foregående krav, hvor den indgivne dosis budesonid er 50-500 pg pr. aktivering.
10. Inhalator (10) ifølge et hvilket som helst foregående krav, hvor den indgivne dosis formoterol er 1-20 pg pr. aktivering.
11. Inhalator (10) ifølge et hvilket som helst foregående krav, hvor den indgivne dosis budesonid/formoterol i ug er 80/4,5, 160/4,5 eller 320/9 pr. aktivering.
12. Inhalator (10) ifølge et hvilket som helst foregående krav til anvendelse i behandling af en åndedræts sygdom.
13. Inhalator (10) til anvendelse ifølge krav 12, hvor åndedræts sygdommen er astma eller kronisk obstruktiv lungesygdom.
14. Inhalator (10) til anvendelse ifølge krav 13, hvor astmaen er mild, moderat eller svær astma klassificeret som GINA-stadie 1, 2, 3 eller 4.
15. Farmaceutisk sammensætning til inhalation, hvor sammensætningen består af aktiv bestanddel og bærer, og den aktive bestanddel omfatter mikroniseret formoterolfumarat og mikroniseret budesonid, kendetegnet ved, at bæreren består af lactose med en partikelstørrelsesfordeling på dlO = 20-65 pm, d50 = 80-120 pm, d90 = 130-180 pm og <10 pm = <10%.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB1321712.0A GB201321712D0 (en) | 2013-12-09 | 2013-12-09 | Dry Powder Inhaler |
| PCT/EP2014/075043 WO2015086276A1 (en) | 2013-12-09 | 2014-11-19 | Dry powder inhaler |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| DK3079744T3 true DK3079744T3 (da) | 2018-08-06 |
Family
ID=50000399
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DK18179164.1T DK3398638T3 (da) | 2013-12-09 | 2014-11-19 | Tørpulverinhalator |
| DK14799494.1T DK3079744T3 (da) | 2013-12-09 | 2014-11-19 | Tørpulverinhalator |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DK18179164.1T DK3398638T3 (da) | 2013-12-09 | 2014-11-19 | Tørpulverinhalator |
Country Status (21)
| Country | Link |
|---|---|
| US (2) | US11020546B2 (da) |
| EP (2) | EP3398638B1 (da) |
| JP (2) | JP6450388B2 (da) |
| KR (2) | KR102296835B1 (da) |
| CN (2) | CN105813675B (da) |
| AR (1) | AR098640A1 (da) |
| AU (2) | AU2014361085B2 (da) |
| BR (1) | BR112016011996B1 (da) |
| CA (1) | CA2931165A1 (da) |
| DK (2) | DK3398638T3 (da) |
| EA (1) | EA034245B1 (da) |
| ES (2) | ES2871820T3 (da) |
| GB (1) | GB201321712D0 (da) |
| HU (2) | HUE039641T2 (da) |
| IL (2) | IL246044B (da) |
| MX (1) | MX385387B (da) |
| PL (2) | PL3398638T3 (da) |
| PT (1) | PT3398638T (da) |
| TR (1) | TR201810066T4 (da) |
| TW (1) | TWI592180B (da) |
| WO (1) | WO2015086276A1 (da) |
Families Citing this family (26)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB201321712D0 (en) | 2013-12-09 | 2014-01-22 | Pharmachemie Bv | Dry Powder Inhaler |
| GB201321717D0 (en) * | 2013-12-09 | 2014-01-22 | Pharmachemie Bv | Inhalable Medicaments |
| WO2016089981A1 (en) * | 2014-12-04 | 2016-06-09 | Carefusion 2200, Inc. | Breath-actuated nebulizer for medicine inhalation |
| USD832997S1 (en) * | 2016-10-21 | 2018-11-06 | Norton (Waterford) Limited | Inhaler |
| USD832998S1 (en) * | 2016-10-21 | 2018-11-06 | Norton (Waterford) Limited | Inhaler |
| USD852947S1 (en) * | 2016-10-21 | 2019-07-02 | Norton (Waterford) Limited | Inhaler |
| US11344685B2 (en) | 2016-11-18 | 2022-05-31 | Norton (Waterford) Limited | Drug delivery device with electronics |
| IL314077A (en) * | 2016-11-18 | 2024-09-01 | Norton Waterford Ltd | inhaler |
| USD853555S1 (en) * | 2017-01-03 | 2019-07-09 | Norton (Waterford) Limited | Inhaler |
| CN107715264B (zh) * | 2017-10-12 | 2021-01-29 | 上海新黄河制药有限公司 | 一种粉雾剂装置制剂粉末团聚物的分散/解聚装置 |
| CN107737393B (zh) * | 2017-10-12 | 2020-08-28 | 上海新黄河制药有限公司 | 一种用于粉雾剂吸入装置的制剂雾化流道 |
| CN110201281B (zh) * | 2018-02-28 | 2021-08-06 | 张江 | 吸入给药装置和吸入给药组合结构 |
| CN109674495B (zh) * | 2018-08-01 | 2021-02-26 | 浙江三创生物科技有限公司 | 给药方法及其装置 |
| USD960349S1 (en) * | 2019-02-04 | 2022-08-09 | Orion Corporation | Inhaler |
| CA3140949A1 (en) * | 2019-05-17 | 2020-11-26 | Norton (Waterford) Limited | Drug delivery device with electronics |
| USD949323S1 (en) * | 2019-07-26 | 2022-04-19 | Lupin Ltd. | Inhaler |
| USD948703S1 (en) * | 2019-07-26 | 2022-04-12 | Lupin Ltd. | Inhaler |
| USD948704S1 (en) * | 2019-07-26 | 2022-04-12 | Lupin Ltd. | Inhaler |
| USD949324S1 (en) * | 2019-07-26 | 2022-04-19 | Lupin Ltd. | Inhaler |
| KR102354664B1 (ko) | 2020-01-07 | 2022-01-24 | 제이디코스파마 주식회사 | 약제 흡입기 |
| KR102420393B1 (ko) | 2020-05-28 | 2022-07-13 | 제이디코스파마 주식회사 | 약제 기화 흡입기 |
| KR102494694B1 (ko) | 2020-11-10 | 2023-02-01 | 권오석 | 약제 기화 흡입기 |
| USD1001996S1 (en) * | 2020-12-16 | 2023-10-17 | Alfred Von Schuckmann | Inhaler |
| GB202102026D0 (en) * | 2021-02-12 | 2021-03-31 | Cambridge Healthcare Innovations Ltd | Medical apparatus and method |
| US11925749B2 (en) * | 2021-03-18 | 2024-03-12 | Funai Electric Co., Ltd. | Venting of pharmaceutical drug delivery device for air flow and humidity control |
| CN114632235B (zh) * | 2022-03-04 | 2023-04-25 | 华中科技大学 | 一种干粉吸入器 |
Family Cites Families (23)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5874063A (en) * | 1991-04-11 | 1999-02-23 | Astra Aktiebolag | Pharmaceutical formulation |
| DK0613371T3 (da) | 1991-12-18 | 2002-05-13 | Astrazeneca Ab | Ny kombination af formoterol og budesonid |
| SE9703407D0 (sv) | 1997-09-19 | 1997-09-19 | Astra Ab | New use |
| PL200941B1 (pl) * | 1998-11-13 | 2009-02-27 | Jagotec Ag | Suchy proszkowy preparat inhalacyjny |
| TWI224511B (en) * | 2000-06-23 | 2004-12-01 | Norton Healthcare Ltd | De-agglomerator for breath-actuated dry powder inhaler |
| TWI224512B (en) * | 2000-06-23 | 2004-12-01 | Norton Healthcare Ltd | Reservoir pressure system for medicament inhaler |
| SE0200312D0 (sv) | 2002-02-01 | 2002-02-01 | Astrazeneca Ab | Novel composition |
| ITMI20051999A1 (it) * | 2005-10-21 | 2007-04-22 | Eratech S R L | Formulazioni inalatorie di farmaci in fora di polvere secca per somministrazione come tale o con nebulizzatore e dotate di elevata erogabilita' respirabilita' e stabilita' |
| GB0602897D0 (en) * | 2006-02-13 | 2006-03-22 | Jagotec Ag | Improvements In Or Relating To Dry Powder Inhaler Devices |
| CN101422436B (zh) * | 2007-10-31 | 2010-12-01 | 江苏正大天晴药业股份有限公司 | 供吸入干粉组合物 |
| US9956170B2 (en) * | 2008-06-26 | 2018-05-01 | 3M Innovative Properties Company | Dry powder pharmaceutical compositions for pulmonary administration, and methods of manufacturing thereof |
| US20100291221A1 (en) | 2009-05-15 | 2010-11-18 | Robert Owen Cook | Method of administering dose-sparing amounts of formoterol fumarate-budesonide combination particles by inhalation |
| GB0918150D0 (en) * | 2009-10-16 | 2009-12-02 | Jagotec Ag | Improved formulations |
| TR200907914A2 (tr) * | 2009-10-20 | 2011-05-23 | B�Lg�� Mahmut | Kortlkosteroid içeren kuru toz formunda farmasötik bileşim. |
| GB0919465D0 (en) | 2009-11-06 | 2009-12-23 | Norton Healthcare Ltd | Airflow adaptor for a breath-actuated dry powder inhaler |
| TR201000680A2 (tr) * | 2010-01-29 | 2011-08-22 | B�Lg�� Mahmut | Tiotropyum, formoterol ve budesonid içeren farmasötik bileşimler |
| WO2011152804A2 (en) * | 2010-06-03 | 2011-12-08 | Mahmut Bilgic | Process for dry powder formulations |
| ES2543427T3 (es) * | 2010-07-08 | 2015-08-19 | Ratiopharm Gmbh | Forma farmacéutica oral de deferasirox |
| JOP20120023B1 (ar) | 2011-02-04 | 2022-03-14 | Novartis Ag | صياغات مساحيق جافة من جسيمات تحتوي على واحد أو اثنين من المواد الفعالة لعلاج امراض ممرات الهواء الانسدادية او الالتهابية |
| DE102011085154A1 (de) * | 2011-10-25 | 2013-04-25 | Evonik Industries Ag | Vorrichtung zur Vermeidung von Ablagerungen an optischen Komponenten im Laser-Sintern |
| GB201205632D0 (en) * | 2012-03-30 | 2012-05-16 | Vectura Ltd | Method and apparatus |
| GB201319265D0 (en) * | 2013-10-31 | 2013-12-18 | Norton Waterford Ltd | Medicament inhaler |
| GB201321712D0 (en) * | 2013-12-09 | 2014-01-22 | Pharmachemie Bv | Dry Powder Inhaler |
-
2013
- 2013-12-09 GB GBGB1321712.0A patent/GB201321712D0/en not_active Ceased
-
2014
- 2014-11-19 PL PL18179164T patent/PL3398638T3/pl unknown
- 2014-11-19 DK DK18179164.1T patent/DK3398638T3/da active
- 2014-11-19 JP JP2016537492A patent/JP6450388B2/ja active Active
- 2014-11-19 AU AU2014361085A patent/AU2014361085B2/en active Active
- 2014-11-19 CA CA2931165A patent/CA2931165A1/en not_active Withdrawn
- 2014-11-19 BR BR112016011996-7A patent/BR112016011996B1/pt active IP Right Grant
- 2014-11-19 ES ES18179164T patent/ES2871820T3/es active Active
- 2014-11-19 EP EP18179164.1A patent/EP3398638B1/en active Active
- 2014-11-19 TR TR2018/10066T patent/TR201810066T4/tr unknown
- 2014-11-19 CN CN201480067032.1A patent/CN105813675B/zh active Active
- 2014-11-19 MX MX2016007182A patent/MX385387B/es unknown
- 2014-11-19 EP EP14799494.1A patent/EP3079744B1/en active Active
- 2014-11-19 HU HUE14799494A patent/HUE039641T2/hu unknown
- 2014-11-19 EA EA201590738A patent/EA034245B1/ru not_active IP Right Cessation
- 2014-11-19 ES ES14799494.1T patent/ES2679523T3/es active Active
- 2014-11-19 KR KR1020167018152A patent/KR102296835B1/ko active Active
- 2014-11-19 CN CN201911112248.6A patent/CN110812634B/zh active Active
- 2014-11-19 HU HUE18179164A patent/HUE055451T2/hu unknown
- 2014-11-19 WO PCT/EP2014/075043 patent/WO2015086276A1/en not_active Ceased
- 2014-11-19 PL PL14799494T patent/PL3079744T3/pl unknown
- 2014-11-19 PT PT181791641T patent/PT3398638T/pt unknown
- 2014-11-19 KR KR1020217027232A patent/KR102460197B1/ko active Active
- 2014-11-19 DK DK14799494.1T patent/DK3079744T3/da active
- 2014-11-19 US US15/101,689 patent/US11020546B2/en active Active
- 2014-12-04 TW TW103142236A patent/TWI592180B/zh active
- 2014-12-05 AR ARP140104541A patent/AR098640A1/es unknown
-
2016
- 2016-06-06 IL IL246044A patent/IL246044B/en active IP Right Grant
-
2018
- 2018-09-06 AU AU2018226472A patent/AU2018226472B2/en active Active
- 2018-12-06 JP JP2018228798A patent/JP6907178B2/ja active Active
-
2020
- 2020-02-12 IL IL272629A patent/IL272629B/en unknown
-
2021
- 2021-05-28 US US17/333,307 patent/US11642475B2/en active Active
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US11642475B2 (en) | Dry powder inhaler | |
| JP6543620B2 (ja) | ドライパウダー吸入器 | |
| KR20170103975A (ko) | 플루티카손 프로피오네이트 및 살메테롤 지나포에이트를 포함하는 건조 분말 흡입기 | |
| AU2018204860A1 (en) | Inhalable medicaments | |
| HK1262834B (en) | Dry powder inhaler | |
| HK1262834A1 (en) | Dry powder inhaler | |
| HK1229272B (en) | Dry powder inhaler | |
| HK1229272A1 (en) | Dry powder inhaler | |
| HK40024930A (en) | Dry powder inhaler | |
| NZ721308B2 (en) | Dry powder inhaler | |
| HK1227340B (zh) | 乾粉吸入器 | |
| HK1227340A1 (en) | Dry powder inhaler |